2021 SEP 21 (NewsRx) - By a News Reporter-Staff News Editor at Disease Prevention Daily - According to news reporting originating from Washington, D.C., by NewsRx journalists, a patent application by the inventors Cosic, Janja (Arlington, MA, US); Faucette, Ryan (Melrose, MA, US); Sexton, Daniel J. (Melrose, MA, US), filed on January 5, 2021, was made available online on September 2, 2021. The assignee for this patent application is Takeda Pharmaceutical Company Limited (Osaka, Japan). Reporters obtained the following quote from the background information supplied by the inventors: "Kininogens are precursors of kinin, such as bradykinin and kallidin. There are two types of human kininogens, high molecular-weight kininogen (HMWK) and low molecular-weight kininogen (LMWK), which are splicing variants. HMWK acts mainly as a cofactor on coagulation and inflammation and is the preferred substrate for plasma kallikrein (pKal)-mediated bradykinin generation.
展开▼
